University of California San Francisco

Publications

Publications

  1. A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  2. Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
    2025 | PubMed
  3. Abstract 2367: Changes in breast hormone signaling and inflammation underlie radiologic features of cancer risk.
    2025 | UCSF Research Profile
  4. 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
    2025 | UCSF Research Profile
  5. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    2025 | PubMed
  6. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    2025 | PubMed
  7. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    2024 | PubMed
  8. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    2024 | PubMed
  9. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    2024 | PubMed
  10. Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
    2024 | PubMed
  11. Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
    2024 | PubMed
  12. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    2024 | UCSF Research Profile
  13. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    2024 | PubMed
  14. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    2024 | PubMed
  15. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial.
    2024 | PubMed
  16. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast.
    2024 | PubMed
  17. International survey on invasive lobular breast cancer identifies priority research questions.
    2024 | PubMed
  18. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    2024 | PubMed
  19. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    2024 | PubMed
  20. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    2024 | PubMed
  21. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    2024 | UCSF Research Profile
  22. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    2024 | UCSF Research Profile
  23. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    2024 | UCSF Research Profile
  24. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    2024 | UCSF Research Profile
  25. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    2024 | UCSF Research Profile
  26. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
    2024 | PubMed
  27. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma.
    2024 | PubMed
  28. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    2024 | PubMed
  29. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    2024 | UCSF Research Profile
  30. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    2024 | UCSF Research Profile
  31. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    2024 | PubMed
  32. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    2024 | UCSF Research Profile
  33. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
    2024 | PubMed
  34. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    2024 | PubMed
  35. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2024 | PubMed
  36. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    2023 | PubMed
  37. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  38. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
    2023 | PubMed
  39. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
    2023 | PubMed
  40. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    2023 | PubMed
  41. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    2023 | UCSF Research Profile
  42. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
    2023 | PubMed
  43. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2023 | PubMed
  44. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
    2023 | PubMed
  45. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  46. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    2023 | PubMed
  47. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    2023 | PubMed
  48. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    2023 | PubMed
  49. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    2023 | PubMed
  50. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
    2023 | PubMed
  51. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
    2023 | PubMed
  52. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    2023 | PubMed
  53. Metabolic Positron Emission Tomography in Breast Cancer.
    2023 | PubMed
  54. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    2023 | PubMed
  55. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    2023 | PubMed
  56. Time to Surgery in Breast Cancer-Is Faster Always Better?
    2023 | PubMed
  57. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    2023 | UCSF Research Profile
  58. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    2023 | UCSF Research Profile
  59. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | PubMed
  60. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  61. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  62. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    2023 | UCSF Research Profile
  63. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    2023 | UCSF Research Profile
  64. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    2023 | UCSF Research Profile
  65. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    2023 | PubMed
  66. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    2023 | PubMed
  67. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    2022 | PubMed
  68. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    2022 | PubMed
  69. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
    2022 | PubMed
  70. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    2022 | PubMed
  71. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    2022 | UCSF Research Profile
  72. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    2022 | PubMed
  73. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    2022 | UCSF Research Profile
  74. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    2022 | PubMed
  75. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    2022 | PubMed
  76. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    2022 | UCSF Research Profile
  77. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    2022 | UCSF Research Profile
  78. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    2022 | PubMed
  79. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    2022 | PubMed
  80. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    2022 | UCSF Research Profile
  81. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    2022 | UCSF Research Profile
  82. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    2022 | UCSF Research Profile
  83. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    2022 | UCSF Research Profile
  84. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    2022 | UCSF Research Profile
  85. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    2021 | PubMed
  86. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    2021 | UCSF Research Profile
  87. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    2021 | PubMed
  88. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    2021 | PubMed
  89. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    2021 | PubMed
  90. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    2021 | PubMed
  91. Correction to: Applications of 3D printing in breast cancer management.
    2021 | PubMed
  92. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    2021 | PubMed
  93. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    2021 | UCSF Research Profile
  94. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
    2021 | PubMed
  95. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    2021 | UCSF Research Profile
  96. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
    2021 | PubMed
  97. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    2021 | PubMed
  98. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
    2021 | PubMed
  99. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    2021 | PubMed
  100. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    2021 | PubMed
  101. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    2021 | UCSF Research Profile
  102. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    2021 | UCSF Research Profile
  103. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    2021 | UCSF Research Profile
  104. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    2021 | UCSF Research Profile
  105. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    2021 | PubMed
  106. Applications of 3D printing in breast cancer management.
    2021 | PubMed
  107. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    2021 | PubMed
  108. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    2021 | PubMed
  109. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    2020 | PubMed
  110. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    2020 | PubMed
  111. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    2020 | UCSF Research Profile
  112. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    2020 | PubMed
  113. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    2020 | PubMed
  114. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    2020 | PubMed
  115. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    2020 | UCSF Research Profile
  116. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  117. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    2020 | PubMed
  118. Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.
    2020 | UCSF Research Profile
  119. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    2020 | UCSF Research Profile
  120. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    2020 | UCSF Research Profile
  121. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    2020 | UCSF Research Profile
  122. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    2020 | UCSF Research Profile
  123. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  124. Pragmatic Trials and Approaches to Transforming Care.
    2020 | UCSF Research Profile
  125. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    2019 | PubMed
  126. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    2019 | PubMed
  127. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
    2019 | PubMed
  128. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    2019 | PubMed
  129. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | PubMed
  130. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
    2019 | PubMed
  131. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    2019 | UCSF Research Profile
  132. Changes in mammographic density following bariatric surgery.
    2019 | PubMed
  133. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    2019 | UCSF Research Profile
  134. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    2019 | UCSF Research Profile
  135. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | UCSF Research Profile
  136. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    2019 | UCSF Research Profile
  137. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2019 | PubMed
  138. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    2018 | PubMed
  139. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  140. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2018 | PubMed
  141. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  142. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  143. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  144. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    2018 | UCSF Research Profile
  145. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    2018 | UCSF Research Profile
  146. Breast tumor location in BRCA mutation carriers and implications for prevention.
    2017 | UCSF Research Profile
  147. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    2016 | PubMed
  148. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    2016 | PubMed
  149. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    2015 | PubMed
  150. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    2015 | PubMed
  151. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    2015 | UCSF Research Profile
  152. Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS.
    2014 | UCSF Research Profile
  153. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    2013 | PubMed
  154. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    2013 | PubMed
  155. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    2012 | PubMed
  156. Biology of breast cancer in Nigerian women: a pilot study.
    2012 | PubMed
  157. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    2012 | PubMed
  158. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    2011 | UCSF Research Profile
  159. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    2011 | UCSF Research Profile
  160. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    2011 | UCSF Research Profile
  161. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    2011 | PubMed
  162. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    2011 | UCSF Research Profile
  163. Benign Thoracic Disease in the Elderly.
    2011 | UCSF Research Profile
  164. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    2011 | PubMed
  165. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    2010 | UCSF Research Profile
  166. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    2010 | UCSF Research Profile
  167. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
    2009 | PubMed
  168. Bacteriologic features of surgical site infections following breast surgery.
    2009 | PubMed
  169. Benign thoracic disease in the elderly.
    2009 | PubMed
  170. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
    2009 | PubMed
  171. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
    2005 | PubMed
  172. Quality-of-life issues in psoriasis.
    2004 | PubMed